Zenas BioPharma’s (ZBIO) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a report released on Monday,Benzinga reports. The firm currently has a $45.00 price objective on the stock.

A number of other research firms have also commented on ZBIO. Evercore ISI initiated coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 15th. Finally, Morgan Stanley increased their price objective on Zenas BioPharma from $34.00 to $37.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.29.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $43.17 on Monday. The company has a market capitalization of $2.32 billion, a P/E ratio of -6.11 and a beta of -1.61. The business has a fifty day simple moving average of $34.45 and a two-hundred day simple moving average of $22.54. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. Zenas BioPharma has a 1 year low of $5.83 and a 1 year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Insiders Place Their Bets

In other Zenas BioPharma news, Director Hongbo Lu purchased 263,160 shares of the stock in a transaction on Tuesday, October 7th. The stock was acquired at an average cost of $19.00 per share, with a total value of $5,000,040.00. Following the completion of the purchase, the director directly owned 321,983 shares of the company’s stock, valued at approximately $6,117,677. This trade represents a 447.38% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Leon O. Moulder, Jr. purchased 36,928 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were acquired at an average price of $20.85 per share, with a total value of $769,948.80. Following the completion of the transaction, the insider owned 36,928 shares of the company’s stock, valued at approximately $769,948.80. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 923,035 shares of company stock valued at $17,628,163 over the last 90 days. Company insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. Quarry LP boosted its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Zenas BioPharma in the third quarter worth $30,000. BNP Paribas Financial Markets raised its holdings in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after buying an additional 1,716 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after buying an additional 2,679 shares during the period. Finally, Sei Investments Co. bought a new stake in Zenas BioPharma in the 2nd quarter worth $118,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.